Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506516 | 0.81 | CNR1 (0.41) | MEN1HTTKMT2ACNR1CNR2 | |
| SCHEMBL28790443 | 0.79 | BACE1 (0.42) | — | |
| SCHEMBL4715047 | 0.79 | LMNA (0.39) | HTTKMT2ACNR1CNR2 | |
| SCHEMBL9816561 | 0.75 | CNR1 (0.41) | HTTKMT2ACNR1CNR2 | |
| SCHEMBL9816349 | 0.75 | CNR1 (0.41) | HTTKMT2ACNR1CNR2 | |
| SCHEMBL2723561 | 0.74 | ALDH1A1 (0.54) | MEN1HTTKMT2A | |
| SCHEMBL2731805 | 0.74 | HIF1A (0.36) | MEN1HTTKMT2ACNR1CNR2 | |
| SCHEMBL1506544 | 0.73 | ALDH1A1 (0.43) | MEN1HTTKMT2A | |
| SCHEMBL31377070 | 0.73 | ALDH1A1 (0.43) | MEN1HTTKMT2A | |
| SCHEMBL21350346 | 0.73 | ALDH1A1 (0.46) | MEN1KMT2ATNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| CN-103269592-B | Cyclic amine substituted oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME CORP. | 2013-12-12 | — | — | US | disclosed |
| EP-2632269-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103269592-A | Cyclic amine substituted oxazolidinone cetp inhibitor | MERCK SHARP & DOHME | 2013-08-28 | — | — | CN | disclosed |
| WO-2012058187-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | CETP, APOB, MTTP | MEN1 3640/4885HTT 3600/4885KMT2A 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.